Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab Journal Article
| Authors: | Shukla, N.; Kobos, R.; Renaud, T.; Teruya-Feldstein, J.; Price, A.; McAllister-Lucas, L.; Steinherz, P. |
| Article Title: | Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab |
| Abstract: | BACKGROUND: Histiocytic sarcoma (HS) is an exceedingly rare tumor and carries a dismal prognosis when patients present with advanced-stage disease. Because of the poor response rates to conventional chemotherapy and the rarity of the disease, no standard of care exists for patients with HS. The authors report the single-agent use of the anti-CD52 antibody alemtuzumab in 2 patients who had advanced-stage HS. METHODS: Two patients with chemotherapy-refractory, metastatic HS with tumors that expressed the CD52 antigen received a prolonged course of treatment with the anti-CD52 monoclonal antibody alemtuzumab. RESULTS: Resected tumor samples from both patients demonstrated CD52 expression. Both patients had marked responses to single-agent alemtuzumab. One patient had a complete response with no evidence of disease for >5 years. The second patient had a major response to alemtuzumab and also remained alive with no evidence of disease for >4 years. CONCLUSIONS: Further studies need to be performed to examine CD52 expression and function in HS as well as the role of alemtuzumab in a larger cohort of patients. However, the clinical impact of single-agent alemtuzumab in the 2 patients described in this report was very encouraging. Given the toxicity and frequent inefficacy of conventional chemotherapy, patients with incompletely resected HS should be strongly considered for alemtuzumab therapy. Copyright © 2011 American Cancer Society. |
| Keywords: | immunohistochemistry; adolescent; cancer chemotherapy; child; human tissue; preschool child; protein expression; prednisone; thalidomide; case report; doxorubicin; advanced cancer; drug dose reduction; drug withdrawal; antineoplastic agents; cancer radiotherapy; cytarabine; methotrexate; nuclear magnetic resonance imaging; positron emission tomography; follow up; laparotomy; pancreas; ki 67 antigen; unindexed drug; computer assisted tomography; infection; etoposide; peritoneal biopsy; cyclophosphamide; dexamethasone; hemoglobin; immunoglobulin; vincristine; tumor regression; drug resistance, neoplasm; ifosfamide; drug dose escalation; fever; lymphocytopenia; rash; intensive care; cancer invasion; liver metastasis; lung metastasis; leukosialin; infant; drug response; fluorodeoxyglucose f 18; neoplasm metastasis; thrombocyte count; protein s 100; lactate dehydrogenase; idiopathic thrombocytopenic purpura; retroperitoneal tumor; leukocyte count; cd4 antigen; drug substitution; mediastinum; nerve sheath tumor; liver biopsy; kidney metastasis; pleura; antibody; lymph node biopsy; lymphadenopathy; retreatment; tioguanine; cd45 antigen; alemtuzumab; leg pain; tachycardia; induction chemotherapy; metastatic; cd52 antigen; cd31 antigen; cladribine; agitation; artificial ventilation; vimentin; histiocytic sarcoma; cd68 antigen; hepatosplenomegaly; refractory; deterioration; petechia; cd45ro antigen; liver fibrosis; metabolic acidosis; asparaginase macrogol; tachypnea; lysozyme; pallor; antibodies, monoclonal, humanized; consolidation chemotherapy; spleen metastasis; extubation; metastatic histiocytic sarcoma |
| Journal Title: | Cancer |
| Volume: | 118 |
| Issue: | 15 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2012-08-01 |
| Start Page: | 3719 |
| End Page: | 3724 |
| Language: | English |
| DOI: | 10.1002/cncr.26712 |
| PROVIDER: | scopus |
| PUBMED: | 22170006 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 1" - "Export Date: 4 September 2012" - "CODEN: CANCA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work